Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.

Abstract

Pituitary adenomas (PA) represent in the majority of cases, benign tumors whose treatment currently associate surgery, medical therapies and radiotherapy in a multidisciplinary approach. While trans-sphenoidal surgery remains, except for prolactin-secreting adenomas, the first-line treatment of PA, it can considerably be hampered by the existence of an invasive and/or aggressive tumor for which medical therapies are often requested. In this review, we extensively discuss, both at molecular and clinical levels, the medical therapies currently used and in development in the different phenotypes of pituitary adenomas.

• Authors: Thomas Cuny, Anne Barlier, Richard Feelders, Georges Weryha, Leo J Hofland, Diego Ferone, Federico Gatto
• Journal: Annales d'endocrinologie (Ann Endocrinol (Paris)) Vol. 76 Issue 1 Pg. 43-58 (Feb 2015) ISSN: 2213-3941 [Electronic] France
• PMID: 25556152 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Chemical References

• Dopamine Agonists
• Somatostatin
• Thyrotropin

Topics

• ACTH-Secreting Pituitary Adenoma (drug therapy)
• Acromegaly (drug therapy)
• Adenoma (drug therapy, pathology)
• Adult
• Dopamine Agonists (therapeutic use)
• Growth Hormone-Secreting Pituitary Adenoma (drug therapy)
• Humans
• Pituitary Neoplasms (drug therapy, pathology)
• Prolactinoma (diet therapy)
• Somatostatin (analogs & derivatives)
• Thyrotropin (metabolism)